Literature DB >> 24316351

[Localized primary bone lymphoma: about four cases].

H Ben Salah1, N Fourati2, M Elloumi3, T Boudawara4, M Frikha5, J Daoud2.   

Abstract

PURPOSE: To study epidemiological, clinical, pathological anatomy and therapeutic results of localized primary bone lymphoma. PATIENTS AND METHODS: Between February 1993 and February 2013, four patients were treated for localized primary bone lymphoma in Sfax's hospitals (Tunisia). Treatment was decided regarding to the age of the patient, his performance status, stage of the disease, lactate dehydrogenase (LDH) and socio-economical conditions of the patient. The therapeutic evaluation was done after chemotherapy and after radiotherapy. There was a clinical, biological and radiological follow-up.
RESULTS: The mean age was 59.5 years. The sex-ratio was 3. Bone localizations were clavicula, femur, humerus and mandibula. All patients had stage I large cell B lymphoma. In 3 cases, imaging showed osteolytic lesions with cortical destruction and extension to soft tissues. One patient had a fracture of the humerus. The treatment consisted in chemotherapy followed by radiotherapy. Three patients were alive with complete remission after a mean follow-up of 76 months.
CONCLUSION: The treatment of primary bone lymphoma is based on a combination of chemotherapy (with or without anti-CD20) and radiotherapy. The prognosis is excellent when it is localized.
Copyright © 2013 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Chimiothérapie; Lymphomes osseux primitifs; Primary bone lymphomas; Radiotherapy; Radiothérapie; Treatment

Mesh:

Substances:

Year:  2013        PMID: 24316351     DOI: 10.1016/j.canrad.2013.11.001

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  1 in total

1.  Primary lymphoma of the tibia in children: Two case reports.

Authors:  Haiqiang Suo; Li Fu; Zhiwei Wang; Hanguang Liang; Zhe Xu; Wei Feng
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.